Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPA

Summary

The purpose of this study is to investigate the safety and tolerability of two dose regimens of IFX-1 as add-on to standard of care (SOC) in subjects with GPA and MPA compared with placebo.

Timeline

Start

2018-10-15

Primary completion

2020-09-10

Completion

2021-05-03

Outcome

Outcome not reported

Stopped (Enrollment): “Due to COVID-19 pandemic outbreak and its impact on overall study activities. All efforts were made to ensure that participants that were enrolled and/or were still in the study will continue to receive treatment and follow-up until study completion.”

Publications

• Serling-Boyd N, Wallace ZS. Management of primary vasculitides with biologic and novel small molecule medications. Curr Opin Rheumatol. 2021 Jan;33(1):8-14. doi: 10.1097/BOR.0000000000000756.

Drugs

Indications